India moves to offer drugs at lower prices through Jan Aushadhi campaign

30 November 2015
gateway-of-india-big

Cheaper generic drugs may soon be commonplace in India with the government aiming to sell around 400 medications at lower prices by this December, through its Jan Aushadhi stores.

From the current 225 unbranded generic drugs available at these stores, the government plans to add medicines to treat diabetes and cancer and have around 425 drugs available at these stores in less than a month's time, reports The Pharma Letter’s India correspondent.

The Jan Aushadhi campaign is an initiative of the Indian government to ensure access to quality medicines. A key initiative under the campaign, launched in 2008, has been to open Jan Aushadhi stores across the country whereby, unbranded quality generic medicines are sold at lower prices, but are equivalent in potency to branded expensive drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics